Takeda, Lundbeck seek FDA review of depression therapy

H. Lundbeck A/S (CSE:LUN) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) announced the submission of an NDA to FDA for vortioxetine ( Lu AA21004) to treat major depressive disorder (MDD). The...